Clinical Trial Update: A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study to learn how BAY2927088 affects blood levels of dabigatran and rosuvastatin when taken together in healthy participants; sponsored by Bayer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Cancer
• Mutant Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• BAY2927088
• Dabigatran (Dabigatran etexilate)
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Bayer | Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Status: COMPLETED